

Mark A Perazella

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5743040/publications.pdf>

Version: 2024-02-01

158
papers

7,447
citations

44069

48
h-index

58581

82
g-index

163
all docs

163
docs citations

163
times ranked

8474
citing authors

#	ARTICLE	IF	CITATIONS
1	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020, 97, 1117-1129.	5.2	407
2	Bisphosphonate nephrotoxicity. <i>Kidney International</i> , 2008, 74, 1385-1393.	5.2	325
3	Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. <i>Radiology</i> , 2020, 294, 660-668.	7.3	309
4	Renal Vulnerability to Drug Toxicity. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1275-1283.	4.5	296
5	Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. <i>American Journal of Kidney Diseases</i> , 2016, 68, 287-291.	1.9	253
6	Onco-Nephrology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1713-1721.	4.5	249
7	Nephrotoxicity From Chemotherapeutic Agents: Clinical Manifestations, Pathobiology, and Prevention/Therapy. <i>Seminars in Nephrology</i> , 2010, 30, 570-581.	1.6	235
8	Current Status of Gadolinium Toxicity in Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 461-469.	4.5	219
9	Drug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity. <i>American Journal of the Medical Sciences</i> , 2003, 325, 349-362.	1.1	194
10	Acute Kidney Injury in Patients with Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 1770-1781.	27.0	177
11	Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. <i>American Journal of Medicine</i> , 2009, 122, 322-328.	1.5	153
12	Diagnostic Value of Urine Microscopy for Differential Diagnosis of Acute Kidney Injury in Hospitalized Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1615-1619.	4.5	149
13	Pharmacology behind Common Drug Nephrotoxicities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1897-1908.	4.5	148
14	Drug-induced nephropathy: an update. <i>Expert Opinion on Drug Safety</i> , 2005, 4, 689-706.	2.4	124
15	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2039-2052.	6.1	121
16	Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?. <i>Kidney International</i> , 2020, 97, 62-74.	5.2	121
17	Drug-induced acute kidney injury: diverse mechanisms of tubular injury. <i>Current Opinion in Critical Care</i> , 2019, 25, 550-557.	3.2	119
18	Renal Replacement Therapies for Prevention of Radiocontrast-induced Nephropathy: A Systematic Review. <i>American Journal of Medicine</i> , 2012, 125, 66-78.e3.	1.5	113

#	ARTICLE	IF	CITATIONS
19	Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019. American Journal of Kidney Diseases, 2019, 73, 258-272.	1.9	112
20	Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology, 2021, 298, 28-35.	7.3	110
21	Urine Microscopy Is Associated with Severity and Worsening of Acute Kidney Injury in Hospitalized Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 402-408.	4.5	106
22	The Urine Sediment as a Biomarker of Kidney Disease. American Journal of Kidney Diseases, 2015, 66, 748-755.	1.9	102
23	Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal of Kidney Diseases, 2015, 66, 857-868.	1.9	100
24	NSAIDs in CKD: Are They Safe?. American Journal of Kidney Diseases, 2020, 76, 546-557.	1.9	99
25	Risk of Poor Outcomes with Novel and Traditional Biomarkers at Clinical AKI Diagnosis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2740-2749.	4.5	98
26	Drug use and nephrotoxicity in the intensive care unit. Kidney International, 2012, 81, 1172-1178.	5.2	96
27	Acute tubular necrosis and pre-renal acute kidney injury: utility of urine microscopy in their evaluation- a systematic review. International Urology and Nephrology, 2010, 42, 425-433.	1.4	90
28	Drug-Induced Acute Interstitial Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2046-2049.	4.5	89
29	Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney International, 2010, 78, 1060-1063.	5.2	83
30	Anticancer Drug-Induced Acute Kidney Injury. Kidney International Reports, 2017, 2, 504-514.	0.8	81
31	Kidney Injury and Repair Biomarkers in Marathon Runners. American Journal of Kidney Diseases, 2017, 70, 252-261.	1.9	81
32	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1291-1299.	4.5	80
33	Cardiorenal complications of immune checkpoint inhibitors. Nature Reviews Nephrology, 2018, 14, 571-588.	9.6	80
34	The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. Journal of the American Society of Nephrology: JASN, 2016, 27, 2227-2237.	6.1	79
35	Onconephrology: The intersections between the kidney and cancer. Ca-A Cancer Journal for Clinicians, 2021, 71, 47-77.	329.8	78
36	PPIs and kidney disease: from AIN to CKD. Journal of Nephrology, 2016, 29, 611-616.	2.0	77

#	ARTICLE	IF	CITATIONS
37	Drug-Induced Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1220-1233.	4.5	75
38	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.8	71
39	New drug toxicities in the onco-nephrology world. <i>Kidney International</i> , 2015, 87, 909-917.	5.2	70
40	Renal cell carcinoma for the nephrologist. <i>Kidney International</i> , 2018, 94, 471-483.	5.2	69
41	Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment. <i>Iranian Journal of Kidney Diseases</i> , 2015, 9, 3-13.	0.1	66
42	Onco-nephrology: a decalogue: Table 1. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 515-519.	0.7	63
43	Proton pump inhibitors and hypomagnesemia: a rare but serious complication. <i>Kidney International</i> , 2013, 83, 553-556.	5.2	61
44	Trimethoprim-Induced Hyperkalaemia. <i>Drug Safety</i> , 2000, 22, 227-236.	3.2	59
45	Three feasible strategies to minimize kidney injury in 'incipient AKI'. <i>Nature Reviews Nephrology</i> , 2013, 9, 484-490.	9.6	58
46	Traditional Urinary Biomarkers in the Assessment of Hospital-Acquired AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 167-174.	4.5	57
47	Clinical Approach to Diagnosing Acute and Chronic Tubulointerstitial Disease. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 57-63.	1.4	57
48	Bile Acid Nephropathy in a Bodybuilder Abusing an Anabolic Androgenic Steroid. <i>American Journal of Kidney Diseases</i> , 2014, 64, 473-476.	1.9	52
49	Renin-angiotensin-aldosterone system: Fundamental aspects and clinical implications in renal and cardiovascular disorders. <i>Journal of Nuclear Cardiology</i> , 2003, 10, 184-196.	2.1	50
50	Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 289-297.	4.5	50
51	Nephrotoxic effects of designer drugs: synthetic is not better!. <i>Nature Reviews Nephrology</i> , 2014, 10, 314-324.	9.6	48
52	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.2	47
53	Increased Mortality in Chronic Kidney Disease: A Call to Action. <i>American Journal of the Medical Sciences</i> , 2006, 331, 150-153.	1.1	44
54	Gadolinium-Induced Nephrogenic Systemic Fibrosis in Patients with Kidney Disease. <i>American Journal of Medicine</i> , 2007, 120, 561-562.	1.5	41

#	ARTICLE	IF	CITATIONS
55	Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 519-525.	2.0	41
56	Acute kidney injury in the patient with cancer. <i>Kidney Research and Clinical Practice</i> , 2019, 38, 295-308.	2.2	41
57	Drug-Induced Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1287-1290.	4.5	39
58	Adverse kidney effects of epidermal growth factor receptor inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1089-1097.	0.7	38
59	COVID-19 therapeutic options for patients with kidney disease. <i>Kidney International</i> , 2020, 97, 1297-1298.	5.2	37
60	The renal effects of ALK inhibitors. <i>Investigational New Drugs</i> , 2016, 34, 643-649.	2.6	34
61	AKI in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1077-1079.	4.5	34
62	COX-2 selective inhibitors: analysis of the renal effects. <i>Expert Opinion on Drug Safety</i> , 2002, 1, 53-64.	2.4	31
63	Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1979-1988.	0.7	31
64	Opening an onconephrology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1503-1510.	0.7	31
65	NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Tissue Deposition of Gadolinium and Development of NSF: A Convergence of Factors. <i>Seminars in Dialysis</i> , 2008, 21, 150-154.	1.3	30
66	Checkmate: kidney injury associated with targeted cancer immunotherapy. <i>Kidney International</i> , 2016, 90, 474-476.	5.2	30
67	Review of select causes of drug-induced AKI. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 367-371.	3.1	27
68	Urine interleukin-9 and tumor necrosis factor- α for prognosis of human acute interstitial nephritis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1851-1858.	0.7	26
69	The Crystalline Nephropathies. <i>Kidney International Reports</i> , 2021, 6, 2942-2957.	0.8	26
70	Imaging Patients With Kidney Disease: How Do We Approach Contrast-Related Toxicity?. <i>American Journal of the Medical Sciences</i> , 2011, 341, 215-221.	1.1	25
71	Tubulointerstitial Injury Associated With Chemotherapeutic Agents. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 56-63.	1.4	25
72	Crystalline-induced kidney disease: a case for urine microscopy. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 131-136.	2.9	23

#	ARTICLE	IF	CITATIONS
73	Urinary Eosinophils in AIN: Farewell to an Old Biomarker?. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1841-1843.	4.5	21
74	Cancer and the Kidney: The Growth of Onco-nephrology. Advances in Chronic Kidney Disease, 2014, 21, 4-6.	1.4	21
75	Review Articles: Approach to Patients with Intradialytic Hypotension: A Focus on Therapeutic Options. Seminars in Dialysis, 1999, 12, 175-181.	1.3	20
76	How to determine kidney function in cancer patients?. European Journal of Cancer, 2020, 132, 141-149.	2.8	20
77	Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. , 2022, 10, e004421.		19
78	Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. American Journal of Physiology - Renal Physiology, 2017, 313, F951-F954.	2.7	17
79	Assessment of Interobserver Reliability of Nephrologist Examination of Urine Sediment. JAMA Network Open, 2020, 3, e2013959.	5.9	17
80	ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?. BioMed Research International, 2014, 2014, 1-7.	1.9	15
81	Impact of Regular or Extended Hemodialysis and Hemodiafiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports, 2017, 2, 1050-1058.	0.8	15
82	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: Commentary. Kidney360, 2020, 1, 166-168.	2.1	15
83	NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Recommendations for Gadolinium-Based Contrast Use in Patients with Kidney Disease. Seminars in Dialysis, 2008, 21, 171-173.	1.3	14
84	Nephrologists as Educators. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 176-189.	4.5	14
85	Toxic Nephropathies: Core Curriculum 2010. American Journal of Kidney Diseases, 2010, 55, 399-409.	1.9	13
86	Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. Kidney International Reports, 2019, 4, 494-499.	0.8	13
87	Crizotinib: Renal Safety Evaluation. Journal of Onco-Nephrology, 2017, 1, 49-56.	0.6	12
88	The nephrotoxicity of new immunotherapies. Expert Review of Clinical Pharmacology, 2019, 12, 513-521.	3.1	12
89	Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. CKJ: Clinical Kidney Journal, 2021, 14, 1301-1306.	2.9	12
90	Improving Cancer Care for Patients With Chronic Kidney Disease. Journal of Clinical Oncology, 2020, 38, 188-192.	1.6	11

#	ARTICLE	IF	CITATIONS
91	Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 2214-2222.	0.7	11
92	Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 37-47.	2.4	10
93	The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2019, 26, 185-197.	1.4	10
94	Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol. <i>Kidney International Reports</i> , 2019, 4, 30-39.	0.8	10
95	Midodrine. <i>Seminars in Dialysis</i> , 1997, 10, 245-247.	1.3	9
96	Cancer and Mortality in Solid-Organ Transplantation: Preventable or Inevitable?. <i>American Journal of Kidney Diseases</i> , 2016, 68, 839-842.	1.9	9
97	Diagnosing acute interstitial nephritis: considerations for clinicians. <i>CKJ: Clinical Kidney Journal</i> , 2019, . .	2.9	9
98	Adverse Drug Effects in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1075-1077.	4.5	9
99	Pharmacology. <i>American Journal of Kidney Diseases</i> , 2005, 46, 1129-1139.	1.9	8
100	The Role of PET Scanning in the Evaluation of Patients With Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 154-161.	1.4	8
101	A case of crystalline nephropathy. <i>Kidney International</i> , 2015, 87, 1265-1266.	5.2	7
102	Paraprotein-Related Kidney Disease: Attack of the Killer M Proteins. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2256-2259.	4.5	7
103	Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. <i>Kidney International Reports</i> , 2022, 7, 1939-1950.	0.8	7
104	Calcium oxalate crystalluria points to primary hyperoxaluria type 1. <i>Kidney International</i> , 2016, 89, 250.	5.2	6
105	AKI in a Hospitalized Patient with Cellulitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 658-664.	4.5	5
106	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 2429-2430.	1.6	5
107	AKI in Multiple Myeloma: Paraproteins, Metabolic Disturbances, and Drug Toxicity. <i>Journal of Onco-Nephrology</i> , 2017, 1, 188-197.	0.6	5
108	The Challenges of Acute Interstitial Nephritis: Time to Standardize. <i>Kidney360</i> , 2021, 2, 1051-1055.	2.1	5

#	ARTICLE	IF	CITATIONS
109	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	1.4	5
110	American Society of Nephrology Quiz and Questionnaire 2013. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1132-1137.	4.5	4
111	American Society of Nephrology Quiz and Questionnaire 2014. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 530-539.	4.5	4
112	<scp>HIV</scp> and <scp>HCV</scp> Medications in End-Stage Renal Disease. <i>Seminars in Dialysis</i> , 2015, 28, 397-403.	1.3	4
113	PARP inhibitors and the Kidney. <i>Journal of Onco-Nephrology</i> , 2021, 5, 42-47.	0.6	4
114	Urine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy. <i>Practical Laboratory Medicine</i> , 2022, 30, e00271.	1.3	4
115	Acute Kidney Injury Related to Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1828.	7.4	3
116	In Case of a Pandemic, Pivot: Moving the National Kidney Foundation Spring Clinical Meeting Online. <i>American Journal of Kidney Diseases</i> , 2021, 77, 1-3.	1.9	3
117	Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?. <i>Kidney360</i> , 2022, 3, 550-553.	2.1	3
118	Macrophages at work: phagocytosis of urinary fungi. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 233-234.	2.9	2
119	Acute Kidney Injury and Mortality in the Elderly: Add Atypical Antipsychotics to the List. <i>American Journal of Kidney Diseases</i> , 2015, 65, 655-658.	1.9	2
120	American Society of Nephrology Quiz and Questionnaire 2015: ESRD/RRT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1313-1320.	4.5	2
121	New Horizons in Nephrology: Update in Onco-Nephrology. <i>Journal of Onco-Nephrology</i> , 2017, 1, 147-150.	0.6	2
122	Introduction to Nephro pharmacology for the Clinician. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1083-1084.	4.5	2
123	Cancer drugs and the glomerulus. <i>Journal of Onco-Nephrology</i> , 2018, 2, 78-91.	0.6	2
124	The adverse kidney effects of cancer immunotherapies. <i>Journal of Onco-Nephrology</i> , 2018, 2, 56-68.	0.6	2
125	The authors reply. <i>Kidney International</i> , 2018, 94, 1238-1239.	5.2	2
126	Acute Nonspecific Illness in an AIDS Patient with Dysphagia. <i>Hospital Practice (1995)</i> , 1994, 29, 39-47.	1.0	1

#	ARTICLE	IF	CITATIONS
127	Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast: What's a Nephrologist to Do?. <i>Seminars in Dialysis</i> , 2008, 21, 121-122.	1.3	1
128	American Society of Nephrology Quiz and Questionnaire 2013. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1319-1327.	4.5	1
129	American Society of Nephrology Quiz and Questionnaire 2014. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 903-909.	4.5	1
130	Phosphate enemas and GFR decline: it's premature to sound the alarm. <i>Kidney International</i> , 2016, 90, 13-15.	5.2	1
131	American Society of Nephrology Quiz and Questionnaire 2015: Glomerular Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 884-890.	4.5	1
132	Growth of the Kidney's Cancer Connection. <i>Journal of Onco-Nephrology</i> , 2017, 1, 71-73.	0.6	1
133	A Rarely Recognized Cause of Acute Kidney Injury in Rhabdomyolysis. <i>American Journal of the Medical Sciences</i> , 2018, 356, e27.	1.1	1
134	Atypical urinary crystals in a patient with acute kidney injury. <i>Journal of Onco-Nephrology</i> , 2019, 3, 169-170.	0.6	1
135	The kidney's cancer connection continues to grow. <i>Journal of Onco-Nephrology</i> , 2020, 4, 26-27.	0.6	1
136	Acute kidney injury in a patient with lymphoma. <i>Journal of Onco-Nephrology</i> , 2020, 4, 66-67.	0.6	1
137	A Hospital-Based Program to Reduce Central Line-Associated Bloodstream Infections among Hospitalized Patients Receiving Hemodialysis Using a Central Venous Catheter for Vascular Access. <i>Nephrology Nursing Journal</i> , 2019, 46, 587-590.	0.2	1
138	Severe AKI in a Patient on Multiple Antimicrobial Agents for Leg Infection. <i>Kidney360</i> , 2022, 3, 405-406.	2.1	1
139	Fellows Forum in Dialysis edited by Mark A. Perazella: Chemical Ablation of Parathyroid Hyperplasia for Recurrent Secondary Hyperparathyroidism in an Autograft. <i>Seminars in Dialysis</i> , 1998, 11, 249-252.	1.3	0
140	Recurrent flank pain from 'lobster claw'. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 274-275.	2.9	0
141	Magnetic Resonance Imaging in ESRD Patients: What are the Options?. <i>Seminars in Dialysis</i> , 2014, 27, 610-613.	1.3	0
142	The Authors Reply. <i>Kidney International</i> , 2015, 88, 200.	5.2	0
143	Mistakes We Make in Dialysis: An Introduction. <i>Seminars in Dialysis</i> , 2016, 29, 257-257.	1.3	0
144	American Society of Nephrology Quiz and Questionnaire 2015. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 735-744.	4.5	0

#	ARTICLE	IF	CITATIONS
145	American Society of Nephrology Quiz and Questionnaire 2015: Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1114-1122.	4.5	0
146	Commentary. Clinical Chemistry, 2016, 62, 440-441.	3.2	0
147	Crying kidneys: Bilateral renal contrast leak. Journal of Onco-Nephrology, 2019, 3, 171-173.	0.6	0
148	The changing of the guard. Seminars in Dialysis, 2019, 32, 482-484.	1.3	0
149	Evolution of the kidney's cancer connection. Journal of Onco-Nephrology, 2019, 3, 88-91.	0.6	0
150	In Reply to "Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus". Kidney Medicine, 2020, 2, 501.	2.0	0
151	Can NSAIDs Be Used Safely for Analgesia in Patients with CKD?: COMMENTARY. Kidney360, 2020, 1, 1192-1194.	2.1	0
152	Genes, COVID-19 and phenotype. CKJ: Clinical Kidney Journal, 2021, 14, 1485-1487.	2.9	0
153	Medical Management of Kidney and Electrolyte Disorders. Annals of Internal Medicine, 2001, 135, 392.	3.9	0
154	Diagnostic Testing in AKI: Let's Move the Field Forward. Journal of Hospital Medicine, 2017, 12, 380-381.	1.4	0
155	Severe Orthostatic Hypotension Complicating Multiple Myeloma. Journal of Onco-Nephrology, 2017, 1, e8-e12.	0.6	0
156	A Patient with Nephrotic Syndrome and Acute Flank Pain. Kidney360, 2020, 1, 74-75.	2.1	0
157	Clinical Images in Nephrology and Dialysis. Kidney360, 2020, 1, 5-5.	2.1	0
158	Introduction to Kidney360. Kidney360, 2020, 1, 3-4.	2.1	0